Kornimate/medical-research-clean huggingface dataset:
acute effects of cycling dual-task in parkinson´s disease.

Conditions: Parkinson Disease

Summary: taking into account the process of functional and cognitive evolution that patients with parkinson's disease experience throughout the pathology, the objective of this study is to evaluate the acute effects of aerobic exercise in forced cycling performed with lower limbs and freecycling of upper limbs combined with cognitive stimuli on attention, exploration skills, and short-term motor skills in people with parkinson's disease.


Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease * present stage between i and iii on the hoenh and yarh scale * being able to move autonomously exclusion criteria: * moderate-severe cognitive impairment (mini-mental test \> 24) * comorbidity that discourages the practice of physical exercise and that allows performing all scheduled assessments * severe visual alterations that prevent the development of the session
autologous cell therapy for stress urinary incontinence in males following prostate surgery

Conditions: Urinary Incontinence; Stress; Urination Disorders; Urologic Diseases; Lower Urinary Tract Symptoms; Urological Manifestations

Summary: to study the safety and potential efficacy of autologous muscle derived cells for urinary sphincter repair (amdc-usr) for the treatment of male stress urinary incontinence (sui) for patients that have undergone prior prostate surgery.

this preliminary, prospective, single-arm clinical study will evaluate the safety and potential efficacy of autologous muscle derived cells for urinary sphincter repair (amdc-usr) for the treatment of male stress urinary incontinence (sui) that develops following prostate surgery.

Eligibility criteria:
inclusion criteria: * male, at least 18 years old, with primary symptoms of sui following prostate surgery, * patient has undergone prostate surgery but has not undergone radiation therapy, cryotherapy, or high-intensity focused ultrasound of the prostate, * sui severity should be ≥10 g and \<400 g of urine leakage over 24 hours, * patient has failed to achieve acceptable resolution of sui symptoms following prior therapy. exclusion criteria: * symptoms of only urge urinary incontinence, * symptoms of stress urinary incontinence prior to prostate surgery, * routinely has more than 2 episodes of awakening to void during normal sleeping hours, * compromised immune system due to disease state, chronic corticosteroid use, or other immunosuppressive therapy, * previously treated with a periurethral balloon or adjustable sling for urinary incontinence, * symptoms of overflow incontinence * additional medical restrictions as specified in the clinical investigation plan, * additional anatomical restrictions as specified in the clinical investigation plan.

Keywords: urinary incontinence, stress tissue therapy (cell therapy)
implitapide in patients with hypertriglyceridemia (htg) on maximal, concurrent triglyceride-lowering therapy

Conditions: Hypertriglyceridemia

Summary: the purpose of this study is to determine if implitapide is effective in lowering triglyceride (tg) levels in patients with fredrickson type i or v hypertriglyceridemia where the maximum tolerable medication and diet were not sufficient.


Eligibility criteria:
inclusion criteria: in order to participate in this study, patients must meet all of the following inclusion criteria: * be between 8 and 70 years old with diagnosis of fredrickson type i or v htg * be stable on current maximum tolerated triglyceride lowering therapy * have a fasting tg level of at least 880 mg/dl (10 mmol/l) * be male or nonpregnant, nonbreastfeeding female. the women in the study must be surgically sterile, postmenopausal or must practice an effective method of birth control * must be able to give informed consent or if under the age of 18, parents or legal guardians must give their informed consent * meet body weight requirements exclusion criteria: * recent heart attack, coronary artery intervention, coronary bypass surgery, or stroke. * patients with class 3 or 4 heart failure * uncontrolled hypothyroidism or other uncontrolled endocrine disease * known, clinically significant eye abnormalities, such as cataracts * history of hepatic disease or ast or alt levels greater than 1.5 x uln at visit 1 * alkaline phosphatase greater than 2 times uln * serum creatinine greater than 2.0 mg/dl * liver cirrhosis and severe liver steatosis * clinically significant infection, malignancy, or psychosis * use of oral anticoagulants or digoxin unless the dose is stable and is regularly monitored * participation in any other investigational study within the last 30 days * breastfeeding or pregnant * current drug or alcohol abuse * serious or unstable medical conditions that would compromise the patient's safety or successful participation in the study * unwillingness to comply with study procedures or unwillingness to cooperate fully

Keywords: htg hypertriglyceridemia, fredrickson type i hypertriglyceridemia, fredrickson type v
to evaluate the feasibility of collecting duodenal fluid with simba capsules

Conditions: Liver Cirrhosis

Summary: in this study, the feasibility to use simba (small intestinal microbiome aspiration) capsules to collect small intestinal microbiome and metabolome information will be evaluated in patients with liver cirrhosis. furthermore, the comparability oral, fecal and small intestinal microbiome and metabolome composition based on similarities and differences in 16s sequencing data and nmr metabolomics data will be evaluated.


Eligibility criteria:
inclusion criteria: * age above 18 years * written informed consent * liver cirrhosis diagnosis by clinical/radiological/histological features * able to swallow a size-00 capsule (23mm length and 8mm width) exclusion criteria: * inability to give informed consent * prior gastrointestinal disease, surgery, or radiation treatment which, in the investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion, including, e.g., achalasia, eosinophilic esophagitis, cancer diagnosis or previous esophageal, gastric, small intestinal, or colonic surgery. appendectomy or cholecystectomy more than 3 months before the screening visit is acceptable. * history of known structural gastrointestinal abnormalities such as structures or fistulas leading to mechanical obstruction. * known history abdominal radiation treatment. * use of any medications in the week prior to the screening study visit, unless part of regular treatment, that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, glp-1 analogues); laxative use is allowed if it is kept unchanged in the week prior to the study visit. proton pump inhibitors (ppis) are allowed provided a wash-out period of 48 h before swallowing simba capsules and ppi treatment is resumed only 4 hours thereafter. * organic motility disorder, including gastroparesis, intestinal pseudo-obstruction, systemic sclerosis, ogilvie's syndrome. * any significant heart, liver, lung, kidney, blood, endocrine or nervous system disease, which in the opinion of the investigator, would adversely affect study safety or outcome. * history of oropharyngeal dysphagia, or other swallowing disorder with a risk of capsule aspiration. * antibiotic use (except for topical use) ≤ 12 weeks prior to screening. potential participants may be eligible once a 12-week washout is completed. * consumption of probiotic or prebiotic supplements within 1 month prior to screening. potential participants may be eligible once a 1-month washout is completed. * any prior fecal microbiota transplantation. * colon cleanses/bowel prep for 2 weeks * pregnant or breastfeeding. * planning to become pregnant. * are scheduled for an mri at any time during the study. potential participants may be eligible to participate once their mri procedure is completed. * history of less than three (3) bowel movements per week.

Keywords: microbiome metabolome 16s rrna nmr pilot study duodenal microbiome liver cirrhosis simba capsule metabolomics
reduction of tacrolimus dose in association with mycophenolate mofetil after liver transplantation

Conditions: Evidence of Liver Transplantation

Summary: the prevention of graft rejection after liver transplantation benefits nowadays from a variety of newly developed immunosuppressive agents. this allows more flexible and individualized immunoprophylaxis and gives an opportunity to reduce the long-term side effects (hypertension, renal failure, diabetes, etc.) of immunosuppression. the purpose of this study is to evaluate, in liver transplanted patients, if low doses of tacrolimus, given in combination with mycophenolate mofetil, can result in a lower rate of long-term side effects without increasing the rate of graft rejection.

tacrolimus and mycophenolate mofetil are currently approved immunosuppressive agents for the prevention of acute and chronic rejection in liver transplantation. adverse effects of tacrolimus are dose-dependent and appear early after the onset of treatment. to prevent side effects, we propose to combine reduced doses of tacrolimus with another immunosuppressant, i.e. mycophenolate mofetil, administered at usual doses. this study evaluates the interest of this combination and, subsequently, the pharmacokinetics of mycophenolate mofetil in this therapeutic context. patients undergoing liver transplantation will be randomized to tacrolimus at normal doses or to the combination of tacrolimus at half doses and mycophenolate mofetil. a corticotherapy will be associated in both groups. the safety will be evaluated on the number of graft rejections between day 1 after transplantation and week 48; the onset of complications (hypertension, renal failure, diabetes, etc.) will allow to evaluate the efficacy of both treatment schedules.

Eligibility criteria:
inclusion criteria: * adults over 18 years of age * primary liver transplantation * immunosuppressive treatment associating tacrolimus and steroids at low doses (\< 20 mg/d) * written informed consent non-inclusion criteria: * pregnancy or ineffective contraception * immunosuppressive treatment * blood group incompatibility with the donor * autoimmune hepatitis * fulminant hepatitis * primary sclerosing cholangitis * combined transplantations * reduced liver * living donor * treated hypertension and/or diastolic pressure ≥ 90 mmhg and/or systolic pressure ≥ 140 mmhg, * acute or chronic renal failure(creatininemia ≥ 130 μmol/l) before transplantation * treated diabetes and/or fasting glycemia ≥ 7 mmol/l * treated hypercholesterolemia and/or cholesterolemia ≥ 7 mmol/l * post-operative creatininemia ≥ 200 μmol/l

Keywords: immunosuppression liver transplantation acute graft rejection treatment combination
effects of intravenous anesthesia and balanced anesthesia on flash visual evoked potentials

Conditions: Brain Tumor Adult

Summary: intraoperative flash visual evoked potentials (fveps) could monitor visual function during neurosurgery. there are fewer reports comparing the effects of sevoflurane-propofol balanced anesthesia and propofol-based total intravenous anesthesia under comparable bispectral index (bis) levels on the amplitude and latency of flash visual evoked potentials (fveps) for sellar or parasellar tumors resection neurosurgeries.

the overall incidence rate of sellar tumors is 10-20% of brain tumors. most of the initial symptoms of this tumor are visual or visual impairment. one of the primary complications of these operations is visual impairment, which directly relates to the quality of patients' life. flash visual evoked potentials (fveps) is an important means of intraoperative visual function evaluation under general anesthesia. intraoperative visual function damage can be avoided or reduced by observing the changing of fveps waves to guide the choice of surgical path. however, since the diversity of anesthetic drugs and methods, there is still a great uncertainty impact on fveps, which will interfere with the interpretation and judgment of surgeons and neuroelectrophysiological physicians respect to the changes of fveps amplitude and latency, and further affect the operation decision-making. therefore, it is urgent to establish a perfect anesthesia method for intraoperative monitoring of fveps. although total intravenous anesthesia has been widely accepted for fveps monitoring, there are still some limitations, such as the possibility of intraoperative body movement and cough due to the restriction of muscle relaxant use under electrophysiological monitoring, as well as the depression on fveps of high maintained dosage under total intravenous anesthesia. the purpose of this study was to investigate the feasibility of fveps monitoring during endoscopic sellar tumor resection under combined intravenous anesthesia compared with total intravenous anesthesia.

Eligibility criteria:
inclusion criteria: 1. age 18-65 years; 2. asa i-iii; 3. elective sellar or parasellar tumors resection; 4. informed written consent exclusion criteria: 1. preoperative visual acuity\<0.3; 2. bmi\>30kg/cm2; 3. uncontrolled hypertension, diabetes or cardiac diseases; 4. preoperative cognitive disorders; 5. sedatives, alcohol or analgesic addiction history; 6. allergy to drugs of this study or contact allergy to silicone products
effects of muscle energy technique with and without stationary cycling on toe walking with asd

Conditions: Autism Spectrum Disorder

Summary: in autism spectrum disorder (asd) is a developmental disability caused by differences in the brain. people with asd often have problems with social communication and interaction, and restricted or repetitive behaviors or interests. people with asd may also have different ways of learning, moving, or paying attention. the aim of this thesis is effects of muscle energy technique with and without stationary cycling on toe walking children with autism spectrum disorder this study seeks to explore whether the synergistic application of these interventions can provide a more comprehensive and effective approach in managing the debilitating symptoms associated with toe walking in autistic children.

. the study\&#39;s sample size will be 26 participants. inclusion criteria for this study will be: diagnosed autistic between ages 4-10 years, diagnosed autistic children, treatment was given to each of the participants for 3 days a week and for 8 weeks. inclusion criteria were all gender with the age group of 4-10 years, participants diagnosed cases of autism spectrum disease with toe walking and their exclusion criteria were suspected but undiagnosed cases of asd, the presence of any limb deformities , autistic children with mr, and unwillingness of participant or parents to be a part of the study. an rct included 26 diagnosed autistic children as per inclusion criteria the subjects were divided into two groups, i.e., group a and b, the group a was given met with stationary bicycling whereas group b was given met without stationary bi-cycling participants were clinically examined. dynamometer, foot posture index, observational gait scale, and parent report of percentage of time toe walking,

Eligibility criteria:
inclusion criteria: * children with diagnosed autism . * aged between 4 to 10 years. * autistic children with toe-walking * regular for follow-up * both gender included exclusion criteria: * children with comorbidities . * children with mild cognitive dysfunction * children less then 4 year or older than 10 years.. * autistic children with limb deformity * autistic children with mental retardation.

Keywords: autism spectrum disorder muscle energy technique toe-walking stationary cycling
post operative hyponatremia in the renal transplant population

Conditions: Hyponatremia

Summary: this study is designed to determine the causes of low sodium (salt) in the body fluids outside the cells for patients who have received a kidney transplant at the mayo clinic of florida. the investigators will look at data collected on previous transplant patients at the mayo clinic to determine if the low sodium levels could be related to factors occurring in the course of surgery. the investigators hypothesize that the intravenous fluid used in the surgery, which is about half the concentration of normal saline, could contribute to the low sodium levels.

this study is designed to determine the cause of post operative hyponatremia in renal transplant patients at the mayo clinic of florida. recently, the investigators have noted a trend in post-operative hyponatremia (low serum sodium) in patients who are recipients of both living donor and cadaveric kidneys. to improve the quality of care of this patient population, the investigators propose the investigation of the sources of this decline in serum sodium levels to determine if this is preventable. the investigators propose that a potential source of post-operative hyponatremia may be related to intra-operative factors. currently, the intravenous fluid of choice used intra-operatively is 0.45% normal saline. the investigators hypothesize that this fluid choice contributes to post-operative hyponatremia. to further investigate this the investigators will perform a retrospective review using the renal transplant database to collect data regarding pre-operative diagnoses, co-morbidities, and method of dialysis used in the pre-transplant period. pre-operative serum sodium level will be compared to post-operative serum sodium levels. data including post-operative complications, need and reasons for post-operative dialysis, and hospital course will also be collected. once the data are analyzed and a primary source or sources are identified as causative agents for post-operative hyponatremia, an intervention to prevent a decline in serum sodium post-operatively will be planned for future study.

Eligibility criteria:
inclusion criteria: -presenting to hospital for renal transplantation exclusion criteria: -renal transplant recipients who received simultaneous transplantation of a liver, heart, or lung

Keywords: hyponatremia renal transplant
radiation-associated carotid artery disease in patients with nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma; Carotid Artery Diseases

Summary: radiation-associated carotid vasculopathy is a common late sequelae in patients with head and neck cancer, which correlates with the incidence of stroke. currently, little is known about the incidence of radiation-associated carotid vasculopahty in the context of intensity-modulated radiation therapy (imrt). the aim of this study is to determine whether imrt will increase the incidence of carotid vasculopathy in patients with nasopharyngeal carcinoma (npc).


Eligibility criteria:
inclusion criteria: * signed inform consent * age more than 18 years old * ecog 0-2 * pathologic diagnosed, non-metastatic npc * either untreated or treated by definitive imrt 3 years ago * did not receive radiation to the head and neck region prior to the diagnosis of npc * if the patient received definitive imrt 3 years ago because of npc, he or she did not receive a second course of radiation due to local relapse * no prior surgery of head and neck exclusion criteria: * prior history of cardiovascular disease before the diagnosis of npc * prior radiation to head and neck before the diagnosis of npc * prior surgery of head and neck * pregnant or lactating women

Keywords: intima media thickness
the impact of therapeutic alliance in the rehabilitation of knee osteoarthritis.

Conditions: Knee Osteoarthritis

Summary: the therapeutic alliance (ta) is the working relationship or positive social bond between the patient and the therapist. ta is based on collaboration, communication, empathy of the therapist and mutual respect. fostering an enhanced therapeutic alliance is a low-cost, therapist-dependent strategy that can accompany any clinical intervention. growing evidence suggests that the ta plays a pivotal role in clinical outcomes in psychotherapy, medicine and physiotherapy interventions for chronic low back pain. on the other hand, therapeutic exercise is an economic, accessible and simple intervention strategy that has proven to be effective and safe to decrease pain and improve physical function in people with knee osteoarthritis (oa). to date, the role of ta in the management of knee oa is unknown. we hypothesized that a therapeutic exercise protocol accompanied by an enhanced ta could reduce the severity of symptoms and improve function in patients with symptomatic knee oa.

the objective of this randomized clinical trial will be to determine the effects of different levels of ta during the application of a therapeutic exercise program on pain intensity, pressure pain thresholds and function in patients with symptomatic knee oa.

Eligibility criteria:
inclusion criteria: - people aged 45 to 65 years with a clinical and radiographic diagnosis of knee osteoarthritis (grade i-iii according to kellgren and lawrance), symptomatic with pain intensity between 3 and 8 points in the pi-nrs with at least 3 months duration, resulting in a mild to moderate level of disability (womac). exclusion criteria: - people with other musculoskeletal, neurological, or immune conditions that cause pain or functional limitation in the lower extremities (hip osteoarthritis, patellar tendinopathy, sprains, radiculopathies, rheumatoid arthritis, systemic lupus erythematosus), history of trauma less than a year ago ( knee fractures, meniscal or ligament tears) or surgery of any kind on the lower extremity. knee mobility less than 90º flexion. people in treatment with oral or intra-articular corticosteroids, antibiotics or exogenous opioids of any kind, with unstable cardiovascular, respiratory, systemic or metabolic conditions that do not allow physical exercise.

Keywords: therapeutic alliance professional-patient relations pain osteoarthritis exercise therapy.
local anesthetic in total knee arthroplasty (tka): volume versus concentration

Conditions: Postoperative Pain; Analgesic Efficacy

Summary: in a randomized, double-blind, cross-over trial, 48 patients scheduled for total knee arthroplasty with placement of an intracapsular catheter will be randomized to receive bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/ml) or low volume/high concentration (10 ml, 10 mg/ml) 6 and 24 hours postoperatively, and pain will be assessed at rest and with mobilization for 2 hours after injections.


Eligibility criteria:
inclusion criteria: * scheduled for total knee arthroplasty * able to give informed oral and written consent to participate exclusion criteria: * treatment with opioids or steroids, rheumatoid arthritis or other immunological diseases * history of stroke or any neurological or psychiatric disease potentially influencing pain perception (e.g. depression, diabetic neuropathy etc.) * allergies to any of the drugs administered.

Keywords: total knee arthroplasty postoperative pain
comparison of alignment efficiency of steel vs elastomeric ligatures in lower anterior teeth

Conditions: Malocclusion of Anterior Teeth

Summary: to compare the treatment time required by elastomeric ligatures and steel ligatures, in days, to achieve complete alignment of the lower anterior teeth.

treatment time required to achieve alignment by two ligation methods will help us in future to choose a better method. the two methods study are elastomeric ligature and steel ligature.

Eligibility criteria:
inclusion criteria: 1. patients coming for fixed orthodontic treatment requiring premolar extraction in mandibular arch. 2. age 12-18 years. 3. no adjunct therapeutic intervention involving functional or orthopaedic appliances. 4. little's irregularity index score of 7-9mm. exclusion criteria: 1. patients with systemic conditions and taking medications affecting tooth movement. 2. lower anterior teeth that are missing, impacted or unerupted, or have fractured crown, restorations, enamel defects, caries. 3. poor periodontal health

Keywords: orthodontic treatment ligature type steel ligature elastomeric ligature alignment time